What is the Dementia Consortium?
The Dementia Consortium is a private-charity partnership between Alzheimer’s Research UK, the pharmaceutical companies Abbvie, Astex Pharmaceuticals, Eisai, Johnson & Johnson, Lilly and MSD and the partner research organisations Charles River Laboratories and Evotec. Launched in 2014, the aim of the Dementia Consortium is to accelerate early stage drug discovery, providing academic researchers with the funding, expertise and project management resources to capitalise on new emerging drug targets.
The case for the Dementia Consortium
Neurodegenerative diseases that cause dementia are our biggest medical challenge. Dementia affects 820,000 people in the UK today and nearly 40 million worldwide. As populations age, the worldwide prevalence of dementia is expected to double every twenty years. Millions of lives will be blighted by these diseases. As well as the enormous social cost, neurodegenerative disease carries an enormous economic impact. In the UK alone, dementia has an economic cost of £23bn, which is greater than heart disease and cancer combined. The Dementia Consortium is focused on fast-tracking new treatments to find an answer to the neurodegenerative diseases that cause dementia.
Future application deadlines will be announced in due course – for further information please
contact us at email@example.com
Please see our statement on COVID-19